Intravitreal injection of conbercept for aggressive posterior retinopathy of prematurity
10.3760/cma.j.issn.1005-1015.2017.02.008
- VernacularTitle:康柏西普玻璃体腔注射治疗急进性后极部早产儿视网膜病变的疗效观察
- Author:
Yong CHENG
;
Jianhong LIANG
;
Xiaoxin LI
- Keywords:
Retinopathy of prematurity/ therapy;
Angiogenesis inhibitors/therapeutic use;
Antibodies,monoclonal/therapeutic use
- From:
Chinese Journal of Ocular Fundus Diseases
2017;33(2):144-147
- CountryChina
- Language:Chinese
-
Abstract:
Objective To observe the effects of intravitreal injection of conbercept for aggressive posterior retinopathy of prematurity (AP-ROP).Methods It is a retrospective case study.Twenty-one patients (40 eyes) with AP-ROP were enrolled in this study.There were 9 males (18 eyes) and 12 females (22 eyes),with the mean gestational age of (28.30±1.79) weeks and the mean birth weight of (1 021.40±316.70) g.All the lesions of 40 eyes were located in posterior zone,with 24 eyes in zone Ⅰ and 16 eyes in zone Ⅱ.All the eyes were treated with intravitreal injection of conbercept 0.025 ml (0.25 mg).During follow-up,nonresponders or patients with deterioration were retreated with intravitreal injection of conbercept or photocoagulation;patients with progressive deterioration to stage 4 had received vitrectomy.At the 1,2,4,8,12,16,20,24 weeks after treatments,the disappearance or decrease of retinal vessel tortuosity and neovascularization,and the growth of the normal retinal vessels toward the peripheral retina were evaluated.Results Thirty-six eyes were cured for only one injection,the cured rate was 90.00%.However,2 eyes (5.00%) had progressed to stage 4 with contractive retinal detachment,which underwent vitrectomy.Two eyes (5.00%) had received twice injections,whose remaining avascular zone area treated by photocoagulation.No major systemic or ocular complications after injection appeared.All lens remained transparent and no iatrogenic retinal hole was occurred during the follow-up.Conclusion Intravitreal injection ofconbercept is effective in the treatment of AP-ROP.